Roland Martin

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis
    Karin Steinbach
    Institute for Neuroimmunology and Clinical MS Research, Hamburg, Germany
    PLoS ONE 6:e26341. 2011
  2. pmc The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response
    Pierre Abramowski
    Institute for Neuroimmunology and Clinical Multiple Sclerosis Research inims, ZMNH, University Medical Center Hamburg Eppendorf, Hamburg, Germany Research Department Cell and Gene Therapy, Clinic for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    PLoS ONE 9:e91970. 2014
  3. ncbi request reprint Sphingosine-1 phosphate and central nervous system
    Roland Martin
    Neuroimmunology and Multiple Sclerosis Research, Clinic for Neurology, University Hospital Zurich, University Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
    Curr Top Microbiol Immunol 378:149-70. 2014
  4. doi request reprint Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
    Roland Martin
    Department of Neuroimmunology and Multiple Sclerosis Research, Neurology Clinic, University Hospital, University Zurich, Zurich, Switzerland
    Clin Immunol 142:9-14. 2012
  5. pmc Nogo receptor is involved in the adhesion of dendritic cells to myelin
    Claire L McDonald
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neuroinflammation 8:113. 2011
  6. ncbi request reprint Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling
    Klarissa Hanja Sturner
    Institute for Neuroimmunology and Clinical Multiple Sclerosis Research INIMS and Clinic for Neurology, Center for Molecular Neurobiology, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    Eur J Immunol 44:1200-12. 2014
  7. pmc Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis
    Andreas Lutterotti
    Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology, 20251 Hamburg, Germany
    Sci Transl Med 5:188ra75. 2013
  8. doi request reprint JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment
    Sven Schippling
    Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, Zurich Department of Neurology, University Hospital Zurich, Zurich
    Ann Neurol 74:622-6. 2013
  9. doi request reprint Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis
    Ilijas Jelcic
    Institute for Neuroimmunology and Clinical Multiple Sclerosis Research, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Mult Scler 18:951-8. 2012
  10. pmc T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors
    Ilijas Jelcic
    University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Virol 87:3393-408. 2013

Collaborators

Detail Information

Publications12

  1. pmc Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis
    Karin Steinbach
    Institute for Neuroimmunology and Clinical MS Research, Hamburg, Germany
    PLoS ONE 6:e26341. 2011
    ..Our study demonstrates the urgent need for a more detailed knowledge on the multifunctional roles of ligands and receptors involved in CNS regeneration failure...
  2. pmc The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response
    Pierre Abramowski
    Institute for Neuroimmunology and Clinical Multiple Sclerosis Research inims, ZMNH, University Medical Center Hamburg Eppendorf, Hamburg, Germany Research Department Cell and Gene Therapy, Clinic for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    PLoS ONE 9:e91970. 2014
    ....
  3. ncbi request reprint Sphingosine-1 phosphate and central nervous system
    Roland Martin
    Neuroimmunology and Multiple Sclerosis Research, Clinic for Neurology, University Hospital Zurich, University Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
    Curr Top Microbiol Immunol 378:149-70. 2014
    ..The present review will concentrate on the latter area and give a brief overview of what is known about S1P/S1PR interactions in the CNS in physiological and pathological conditions. ..
  4. doi request reprint Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
    Roland Martin
    Department of Neuroimmunology and Multiple Sclerosis Research, Neurology Clinic, University Hospital, University Zurich, Zurich, Switzerland
    Clin Immunol 142:9-14. 2012
    ..From these data CD25 inhibition is one of the most promising upcoming treatments of RR-MS and possibly also other autoimmune conditions. Clinical and mechanistic data will be summarized in this short review...
  5. pmc Nogo receptor is involved in the adhesion of dendritic cells to myelin
    Claire L McDonald
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    J Neuroinflammation 8:113. 2011
    ..The exact mechanisms of interaction of immune cells with CNS myelin are, however, poorly understood...
  6. ncbi request reprint Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling
    Klarissa Hanja Sturner
    Institute for Neuroimmunology and Clinical Multiple Sclerosis Research INIMS and Clinic for Neurology, Center for Molecular Neurobiology, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    Eur J Immunol 44:1200-12. 2014
    ..The effects of AKBA on Th17 differentiation and IL-17A release make the compound a good candidate for potential treatment of Th17-driven diseases. ..
  7. pmc Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis
    Andreas Lutterotti
    Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology, 20251 Hamburg, Germany
    Sci Transl Med 5:188ra75. 2013
    ..In summary, this first-in-man clinical trial of autologous peptide-coupled cells in MS patients establishes the feasibility and indicates good tolerability and safety of this therapeutic approach...
  8. doi request reprint JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment
    Sven Schippling
    Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, Zurich Department of Neurology, University Hospital Zurich, Zurich
    Ann Neurol 74:622-6. 2013
    ..GCN should be considered as a JCV CNS manifestation in patients with newly developed, progressive cerebellar signs under natalizumab treatment, especially in cases where cerebellar atrophy can be visualized by magnetic resonance imaging...
  9. doi request reprint Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis
    Ilijas Jelcic
    Institute for Neuroimmunology and Clinical Multiple Sclerosis Research, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Mult Scler 18:951-8. 2012
    ....
  10. pmc T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors
    Ilijas Jelcic
    University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Virol 87:3393-408. 2013
    ..Our data are potentially relevant for the development of vaccines against JCV...
  11. pmc Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data
    Jan Patrick Stellmann
    Institute for Neuroimmunology and Clinical MS Research inims and Department of Neurology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    PLoS ONE 7:e50347. 2012
    ..The causes of these changes are not clear. We consider a better understanding of this phenomenon essential for valuing the effects of new drugs and by designing new trials...
  12. doi request reprint Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis
    Raquel Planas
    Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, University Medical Center Eppendorf, Hamburg, UKE, Germany
    Eur J Immunol 42:790-8. 2012
    ..The ability of natalizumab to influence B-cell migration and homeostasis through the splenic MZ, where JCV has been detected, adds to the list of natalizumab effects and may contribute to PML development by disseminating JCV...